According to Moderna
's latest financial reports the company has a price-to-book ratio of 4.53.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 2.74 | -24.15% |
2022-12-31 | 3.61 | -50.43% |
2021-12-31 | 7.28 | -54.9% |
2020-12-31 | 16.1 | 188.09% |
2019-12-31 | 5.60 | 70.78% |
2018-12-31 | 3.28 | |
2017-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.99 | 10.24% | ๐บ๐ธ USA |
Novartis NVS | 5.17 | 14.10% | ๐จ๐ญ Switzerland |
Merck MRK | 7.89 | 74.15% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | 1.38 | -69.64% | ๐บ๐ธ USA |
Athersys ATHX | -0.0229 | -100.51% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -86.5 | -2,010.69% | ๐บ๐ธ USA |
Arrowhead Pharmaceuticals
ARWR | 5.73 | 26.52% | ๐บ๐ธ USA |